首页> 外国专利> Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams

Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams

机译:生物分子造影剂用于质子或离子束放射治疗的治疗成功和剂量监测

摘要

A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, and signal reactive, capable of being inactivated by delivery of energy thereto. By monitoring the decrease in signal strength of the BMCA, the actual dosage delivered to the target can be determined and monitored. The decrease in BMCA signal strength can also be correlated to the level of destruction of the target, allowing for determination of therapy success.
机译:将生物分子造影剂(BMCA)引入生物有机体中,以便该试剂与该生物体内的靶组织结合或反应。 BMCA还具有信号传递和信号反应性,能够通过向其传递能量来使其失活。通过监视BMCA信号强度的下降,可以确定和监视传递到目标的实际剂量。 BMCA信号强度的降低也可以与靶标的破坏水平相关,从而可以确定治疗成功与否。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号